Company

Halozyme Therapeutics Inc.

HALOBiotechnology

Halozyme Therapeutics Inc., founded in 1998 and headquartered in San Diego, California, develops and commercializes its proprietary ENHANZE enzyme technology to enable subcutaneous delivery of large molecule therapeutics. The company’s reve

Snapshot

Halozyme Therapeutics Inc. is a biotechnology company that has completed 2 disclosed acquisitions and reported $1.40B in latest-year revenue.

Sector
Biotechnology
Ticker
HALO
Revenue (LTM)
$1.40B
Acquisitions
2
Operating margin
33.6%
Latest call
Q1 2026
$1.40B
Revenue (LTM)
2
Acquisitions
33.6%
Operating margin
Q1 2026
Latest call
01 Explore

Everything on Halozyme Therapeutics Inc.

01
Acquisitions
Full M&A history — every deal, price and rationale.
2 deals
02
Financials
Income statement, balance sheet, cash flow and quarterly trend.
Rev $1.40B
03
Earnings
Quarter-by-quarter call transcripts.
4 transcripts · Q1 2026
04
People
Leadership team and board.
View

Financials

View financials

Income statement, balance sheet and cash flow for Halozyme Therapeutics Inc., with quarterly trend. Latest-year revenue $1.40B.

Revenue (FY2025) $1.40B
YoY growth +37.6%
Operating margin 33.6%
Direction Expanding
Gross margin 83.6%
Net margin 22.7%

Earnings

All earnings

Quarter-by-quarter results and management commentary from the earnings calls. Most recent: Q1 2026.

Q1 2026 Transcript Q4 2025 Transcript Q3 2025 Transcript Q2 2025 Transcript

Leadership & board

View leadership

Halozyme Therapeutics, Inc.'s leadership comprises 8 directors and 4 named executive officers, led by Helen I. Torley (President and Chief Executive Officer; Director). Names, tenure and backgrounds are sourced from the latest SEC proxy statement (DEF 14A).

Helen I. TorleyPresident and Chief Executive Officer; Director
Jeffrey W. HendersonBoard Chair; Director
Bernadette ConnaughtonDirector
Matthew L. PosardDirector
Barbara DuncanDirector
Mahesh KrishnanDirector
James LangDirector
Moni MiyashitaDirector
Nicole LaBrosseSenior Vice President, Chief Financial Officer
Mark SnyderSenior Vice President, Chief Legal Officer
Cortney CaudillSenior Vice President, Chief Operating Officer
Michael J. LaBarreFormer Senior Vice President, Chief Technical Officer

Acquisitions

Full history

Halozyme Therapeutics Inc. has completed 2 disclosed acquisitions, largest first.

Halozyme Therapeutics acquires Antares Pharma, Inc.Drug delivery and specialty pharmaceuticals (auto injector platform + testosterone replacement therapy) · 2022 $960 million Halozyme Therapeutics acquires Elektrofi, Inc.Drug delivery technology (ultra-high concentration microparticle formulation for biologics) · 2025 $750 million
SourcesSEC filings · company financials · earnings transcripts Last updated

More companies

CompanyRoper Technologies Inc.CompanyAMETEK Inc.CompanyFortive CorporationCompanyDover CorporationCompanyOkta Inc.CompanyDanaher Corporation

See how VectorShift works for your firm

Request Demo